View Older Stories View More Recent Stories

Apr 16, 2025 06:30PM Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
Mar 25, 2025 04:05PM New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
Mar 19, 2025 05:00PM Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
Feb 24, 2025 04:05PM Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
Feb 19, 2025 05:05PM Veracyte to Participate in Upcoming Investor Conferences
Feb 14, 2025 08:30AM New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
Feb 11, 2025 08:30AM Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
Feb 5, 2025 08:30AM New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
Feb 4, 2025 04:30PM Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
Dec 5, 2024 04:05PM Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
Nov 6, 2024 04:05PM Veracyte Announces Third Quarter 2024 Financial Results
Oct 30, 2024 05:00PM Veracyte to Participate in Upcoming Investor Conferences
Oct 16, 2024 06:43PM Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
Oct 2, 2024 08:20AM New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
Sep 15, 2024 08:45AM New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
Sep 4, 2024 04:05PM Veracyte (VCYT) Appoints Brent Shafer and Tom Miller to its Board
Sep 4, 2024 04:05PM Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
Aug 26, 2024 05:30PM Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Aug 26, 2024 09:00AM Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
Aug 6, 2024 04:05PM Veracyte Announces Second Quarter 2024 Financial Results
Jul 17, 2024 05:00PM Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
Jun 3, 2024 04:05PM Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
May 22, 2024 04:05PM Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
May 15, 2024 05:04PM Veracyte to Participate in Upcoming Investor Conferences
May 7, 2024 04:05PM Veracyte Announces First Quarter 2024 Financial Results
May 6, 2024 04:05PM 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
Apr 22, 2024 05:00PM Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
Apr 22, 2024 08:30AM New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Apr 16, 2024 08:30AM Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Feb 27, 2024 05:55PM Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
Feb 22, 2024 04:05PM Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
Feb 21, 2024 05:00PM Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
Feb 8, 2024 08:00AM Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Feb 6, 2024 08:15AM Veracyte Completes Acquisition of C2i Genomics
Jan 8, 2024 08:09AM Veracyte (VCYT) Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics
Jan 8, 2024 08:00AM Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
Dec 12, 2023 04:30PM Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Dec 1, 2023 04:05PM Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
Nov 29, 2023 08:30AM Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
Nov 22, 2023 08:30AM Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
Nov 7, 2023 04:05PM Veracyte Announces Third Quarter 2023 Financial Results
Nov 7, 2023 04:00PM Veracyte (VCYT) Announces In Vitro Diagnostic Agreement with Illumina (ILMN) to Broaden Availability of Its Tests for Patients Globally
Nov 7, 2023 04:00PM Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
Nov 2, 2023 08:15AM Veracyte to Participate in the Stephens Annual Investment Conference
Oct 27, 2023 08:30AM Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
Oct 17, 2023 08:15AM Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
Oct 12, 2023 09:00AM New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
Oct 4, 2023 04:05PM Veracyte (VCYT) Reports New Data from Phase 3 Trial Further Validating Prognostic Value of Decipher Prostate Genomic Classifier
Oct 4, 2023 04:05PM New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
Sep 28, 2023 04:05PM New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
View More Recent Stories View Older Stories